A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. The study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment? * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed? * How much of the study drug(s) are in the blood at a given time? * Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)?
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem histologicznym rak płuca NSCLC etapu II-IIIB, który można operacyjnie usunąć
- •Widoczne zmiany nowotworowe wykrywalne w badaniach obrazowych
- •Dostępne próbki tkanki guza do badań laboratoryjnych
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (skala ECOG 0-1)
- •Prawidłowa funkcja narządów wewnętrznych i szpiku kostnego
✗ Disqualifies
- •Wcześniejsze chemioterapie lub napromienianie tego guza
- •Obecność określonych zmian genetycznych w guzie (EGFR lub ALK)
- •Poważne uszkodzenie nerwów (grade ≥2)
- •Inny nowotwór wymagający aktywnego leczenia
- •Bardzo wysokie stężenie wapnia we krwi
- •Problemy neurologiczne mogące zwiększać ryzyko powikłań immunologicznych
- •Zaburzenia rytmu serca (wydłużony odstęp QT) lub ryzyko ich występowania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (50)
University of California Irvine
Orange, United States
Orchard Healthcare Research Inc.
Skokie, United States
Karmanos Cancer Institute
Detroit, United States
Detroit Clinical Research Center
Farmington Hills, United States
Morristown Medical Center
Morristown, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Oncology Hematology Care Clinical Trials LLC
Cincinnati, United States
Providence Portland Medical Center
Portland, United States
University Of Nebraska Medical Center
Portland, United States
Lifespan Cancer Institute
Providence, United States
Prairie Lakes Healthcare System
Watertown, United States
University of Tennessee Medical Center
Knoxville, United States
Sarah Cannon Research Institute (SCRI) Oncology Partners
Nashville, United States
Tennessee Oncology
Nashville, United States
BRCC/Oncology & Hematology Associates of SW Virginia
Blacksburg, United States
Oncology Clinical Research Center
Cachoeiro de Itapemirim, Brazil
Instituto Mario Penna
Belo Horizonte, Brazil
Instituto Sul Mineiro De Oncologia LTDA
Pouso Alegre, Brazil
Instituto de Medicina Integral Professor Fernando Figueira
Recife, Brazil
Liga Norte Riograndense Contra o Cancer
Natal, Brazil
Hospital Mae de Deus Integrated Oncology Center
Porto Alegre, Brazil
Hospital Sao Lucas da PUCRS
Porto Alegre, Brazil
Ynova Pesquisa Clinica
Florianópolis, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
São José do Rio Preto, Brazil
Unimed Sorocaba
Sorocaba, Brazil
Hospital Alemao Oswaldo Cruz
São Paulo, Brazil
CHU Rennes
Rennes, France
Centre Hospitalier Intercommunal Toulon - CHITS
Toulon, France
Centre Hospitalier de la Cote Basque
Bayonne, France
Clinique Belharra
Bayonne, France
CHU Grenoble Alpes
Grenoble, France
Montpellier Academic Hospital
Montpellier, France
Institut Curie
Paris, France
Klinikum Kassel GmbH, Hauttumorzentrum
Kassel, Germany
University Medicine Gottingen
Göttingen, Germany
University of Leipzig
Leipzig, Germany
University Hospital RWTH Aachen
Aachen, Germany
Catalan Instituye of Oncology Badalona
Badalona, Spain
Hospital Valdecilla
Santander, Spain
Hospital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria, Spain
Clinica Universidad de Navarra
Pamplona, Spain
MD Anderson Cancer Center
Madrid, Spain
Hospital Universitario Clinico San Carlos
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Hospital Virgen del Rocio
Seville, Spain
Hospital Clinico Universitario Valencia
Valencia, Spain
Consorci Hospital General Universitario de Valencia
Valencia, Spain
Hospital Clinico Lozano Blesa
Zaragoza, Spain
Florya Medical Park Hospital
Istanbul, Turkey (Türkiye)
Trial contact
Clinical Trials Administrator
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.